← Back to Analyst Consensus 
DNA Sell
Ginkgo Bioworks Holdings, Inc.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 13, 2026 | TD Cowen | maintain | Hold → Hold | — | 54% |
| Sep 4, 2026 | BTIG | reiterate | Sell → Sell | — | 52% |
| Aug 7, 2026 | TD Cowen | downgrade | Buy → Hold | — | 54% |
| Mar 12, 2026 | BTIG | maintain | Sell → Sell | — | 52% |
| Jan 8, 2026 | TD Cowen | maintain | Buy → Buy | $12 | 54% |
| Aug 25, 2025 | BTIG | maintain | Sell → Sell | $9 | 52% |
| Sep 20, 2024 | TD Cowen | maintain | Buy → Buy | $10 | 54% |
| Aug 23, 2024 | BTIG | maintain | Sell → Sell | $7 | 52% |
| Jul 9, 2024 | Goldman Sachs | maintain | Sell → Sell | $0.3 | 54% |
| Jun 26, 2024 | BTIG | maintain | Sell → Sell | $0.2 | 52% |
| May 15, 2024 | BTIG | downgrade | Neutral → Sell | $0 | 52% |
| May 15, 2024 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $1 | 54% |
| May 10, 2024 | William Blair | downgrade | Market Perform → Underperform | $0 | 48% |
| Mar 1, 2024 | TD Cowen | maintain | Outperform → Outperform | $3 | 54% |
| Jan 23, 2024 | Goldman Sachs | maintain | Sell → Sell | $1.1 | 54% |
| Jan 22, 2024 | Goldman Sachs | maintain | Sell → Sell | $1.1 | 54% |
| Nov 15, 2023 | Raymond James | downgrade | Outperform → Market Perform | $2.5 | 54% |
| Nov 14, 2023 | Raymond James | downgrade | Outperform → Market Perform | $2.5 | 54% |
| Nov 9, 2023 | BTIG | downgrade | Buy → Neutral | $0 | 52% |
| Jun 5, 2023 | Goldman Sachs | maintain | Sell → Sell | $1.25 | 54% |
| Jun 2, 2023 | Goldman Sachs | downgrade | Neutral → Sell | $1.25 | 54% |
| May 11, 2023 | William Blair | downgrade | Outperform → Market Perform | $0 | 48% |
| Nov 29, 2022 | Berenberg | initiate | — → Buy | $6 | 29% |
| Oct 4, 2022 | Morgan Stanley | initiate | — → Equal-Weight | $5 | 54% |
| Aug 16, 2022 | BTIG | maintain | — → Buy | $6 | 52% |
| Aug 16, 2022 | Raymond James | maintain | — → Outperform | $14.5 | 54% |
| Jun 16, 2022 | Jefferies | maintain | — → Buy | $4.35 | 52% |
| May 18, 2022 | B of A Securities | downgrade | Neutral → Underperform | $3 | 53% |
| Mar 2, 2022 | Cowen & Co. | initiate | — → Outperform | $12 | — |
| Feb 23, 2022 | Goldman Sachs | initiate | — → Neutral | $7 | 54% |
| Feb 1, 2022 | B of A Securities | initiate | — → Neutral | $6 | 53% |
| Jan 28, 2022 | B of A Securities | initiate | — → Buy | $8 | 53% |
| Jan 7, 2022 | BTIG | initiate | — → Buy | $12 | 52% |
| Oct 13, 2021 | Raymond James | initiate | — → Outperform | $14.5 | 54% |
| Oct 12, 2021 | William Blair | initiate | — → Outperform | $0 | 48% |
| Sep 20, 2021 | HSBC | initiate | — → Buy | $14 | 53% |
Price Target Trend
May 26, 2026 Oct 26, 2026
EPS Estimates
+1q —
+1y —
0q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days